Bence Jones proteins are molecules of about 40,000 mol wt present in the urine of many patients with plasma cell malignancy. These microglobulins, which are synthesized in plasma-cell tumors (1, 2) , share many immunochemical and physicochemical features with the larger 6.6 S y-globulins. That Bence Jones proteins are similar to or identical with components of the larger y-globulins has been suggested (3) (4) (5) . Evidence has been recently obtained that microglobulin components similar to Bence Jones proteins may be present in normal urine (6) (7) (8) and serum (9) .
The rate of synthesis and metabolic fate of these proteins are poorly understood, both in malignant plasma cell diseases and in the normal state. Putnam and Hardy (10) and Osserman and associates ( 11 ) observed that newly synthesized Bence Jones protein was excreted rapidly by patients with multiple myeloma; they suggested that massive proteinuria (as high as 50 g per day) may be present and that Bence Jones proteins are excretory products of protein metabolism. It was not clear in these studies whether all the newly synthesized Bence Jones protein was excreted or whether only a part was excreted and the remainder catabolized. Evidence that some Bence Jones protein is catabolized was noted by Meyer and Putnam (12) , who reported that only a fraction of injected C14-labeled Bence Jones protein appeared in the urine of a single patient with multiple myeloma when he was reinjected with his own labeled Bence Jones protein. Rabbits given the same protein also excreted only a part of the injected protein intact. Perkins, Doherty, and Towbin (13) reported after two studies with intravenously administered I131-labeled Bence Jones protein that only 20% of the injected 1131 was excreted bound to protein, the remaining 80%o being excreted as iodide, presumably representing * Submitted for publication July 8, 1963 ; accepted September 26, 1963 (14) , injecting I131-labeled Bence Jones protein into normal and tumor-bearing mice, found that 4 to 48% of the injected J131 was excreted bound to protein, the remainder appearing as iodide. These observations indicate that Bence Jones protein is catabolized as well as excreted in the urine. In addition, observations in ten patients with multiple myeloma and detectable levels of Bence Jones protein in the serum (15) indicate that Bence Jones protein might not be immediately cleared from the circulation and that other factors, such as renal function, might play a part in their metabolic behavior.
The present studies were undertaken to investigate the metabolic behavior of Bence Jones proteins. After the iv injection of I131-labeled Bence Jones protein, the relative contribution of catabolism and urinary loss to the over-all metabolism of Bence Jones proteins was determined. The absolute turnover (synthetic rate) of Bence Jones protein was estimated in patients who were in a steady state of Bence Jones protein production and excretion. Bence Jones protein (BJ) turnover studies differ from studies of albumin and y-globulin turnover in normal subjects in several important features. Urinary protein loss, impaired renal excretion of iodide, and rapid rates of protein catabolism (i.e., very rapid relative to the rates of distribution of the protein and of the excretion of the radioiodide released from the protein) result in an accumulation of radioiodide in the body water. Therefore, the usual parameters of the protein turnover investigation were supplemented by determinations of protein-bound radioactivity and nonprotein-bound (predominantly free iodide) radioactivity in the plasma and urine at intervals of 1 day or less throughout the study.
Bence Bence Jones protein was isolated from the sera of two patients (DR and ZO) by anion exchange chromatography on DEAE-sephadex. Eight ml of plasma from each patient was dialyzed against a hundredfold volume of 0.01 M potassium phosphate buffer, pH 8, as described for the urine samples. The bulk of the 6.6 S 'y-globulins was eluted from the column in the first chromatogram fraction, and the Bence Jones proteins were eluted subsequently with 0.06 to 0.08 M potassium phosphate buffer, pH 8.
Preparation of the purified urinary or serum Bence Jones proteins required about 4 hours. The proteins were promptly labeled with reducing agent-free I"~by the iodine monochloride method of McFarlane (18) . Free radioiodine was removed by dialysis against a sterile solution of 0.14 M NaCl, and the iodinated protein was filtered through a 0.22 Millipore filter. There was less than one mole of iodine per mole of protein (mol wt, 40,000) in the product. Sterile human albumin was added subsequently, providing a protein concentration of 3.5 g per 100 ml to prevent damage to the Bence Jones protein by selfradiation. Before administration, the iodinated proteins were found to be sterile and nonpyrogenic.
Each Bence Jones protein preparation was characterized by ultracentrifugation, starch gel electrophoresis, immunoelectrophoresis and Ouchterlony agar double diffusion tests with polyvalent antigamma globulin antiserum and antiwhole human serum antiserum (15, 17) .
The results are summarized in Table I and Figure 1 . The proteins were seen as a single peak with a sedimentation coefficient (S20w) of 3.4 to 3.8 S in the ultracentrifuge. They exhibited the characteristic reversible thermal insolubility and gave pH-heat precipitation curves of the beta type described by Putnam and associ- ates (16) . The urinary Bence Jones protein preparations were found to be free of other proteins, but the serum preparations also contained some normal y-globulin. The isolated serum Bence Jones protein had antigenic, electrophoretic, ultracentrifugal, and thermal behavior similar to that of the urinary protein from the same patient (15 3) Total body radioactivity = the injected dose less cumulative excretion of radioactivity in the urine and stools. Daily excretion of radioactivity in the stools was always less than 0.2%o of the dose.
4) The total circulating BJ activity and total circulating nonprecipitable activity = the respective serum activities per ml X the plasma volume. The total body radioactivity, the total circulating Bence Jones radioactivity, and the total circulating nonprecipitable radioactivity were plotted as a percentage of the administered dose against time on semilogarithmic paper in Figures 2 to 4. 5) Total body nonprecipitable radioactivity = nonprecipitable 1131 per ml of plasma X the plasma volume X f, where f = the ratio of the total body iodide pool to the plasma iodide pool. The ratio f was not directly measured but was taken to be 8 (see Discussion).
The protein-bound radioactivity lost in the urine and the radioiodide released from the protein after catabolism were expressed as functions of the mean circulating 1131 BJ activity. This method of analysis requires the assumption that catabolism occurs in the plasma compartment (or a compartment in rapid equilibrium with the plasma) but does not require that the total body pool of Bence Jones protein be known, that the pools be in equilibrium, or that the patient be producing Bence Jones protein.
6) Proteinuric rate, as percentage per hour = urinary protein-bound I"i excreted in a period X 100/(integrated mean circulating protein-bound P"' in the period X hours in the period). For the patients with Bence Jones proteinemia and proteinuria, the grams of Bence Jones lost in the urine per day may be calculated from the product of the daily proteinuric rate (Equation 6 ) and the total circulating Bence Jones protein (Equation 2). The values for the grams of BJ protein lost as proteinuria thus calculated were compared to the experimentally deter-mined values for the grams of BJ proteins lost in the urine of these patients, thus providing a check on the accuracy of the estimate of the proteinuric rate.
7) Cataholic rate, as percentage per hour = nonprecipitable P"31 released from BJ in a period X 100/(integrated mean circu ating protein-bound P"31 in the period X hours in the period). In this calculation the nonprecipitable I.8. released from protein breakdown in a urine collection period equals the urinary excretion of radioiodide plus the change in the total body nonprecipitable radioactivity in that period, as determined from Equation 5.
The proteinuric and catabolic rates were determined from each urinary collection period; the values presented in tabulation results represent the mean value for all the periods for a given patient.
8) The ratio of proteinuric (P) to catabolic (C) rates was determined a) from the above values (ratio of Equation 6 to 7), or, alternatively b) by a modification of the cumulative excretion method used by Gitlin, Janeway, and Farr (19) for the analysis of the protein turnover in patients with nephrosis. P: C = cumulative urinary excretion of precipitable 1131 over the whole period of the study/cumulative urinary excretion of nonprecipitable I131 over the whole period of the study. This method assumes that only a negligible quantity of nonprecipitable I" remains in the body water at the completion of the 0.Wl study. This was true in all cases except patient FL, who had significant retention of iodide in the body water. The determination of the P: C ratio from the cumulative excretion of radioactivity does not require that an estimate of the body iodide pool be made, nor that the curve of serum radioactivity be determined. Synthetic rate. The absolute turnover of Bence Jones protein, which in a steady state equals the grams synthesized, may be determined from the product of the total circulating Bence Jones protein and the fraction of the intravascular BJ turning over per unit time. This technique requires an accurate determination of the proteinuric and catabolic rates, the plasma volume, and the serum BJ concentration. Alternatively, the absolute turnover of Bence Jones protein may be determined from the following formula: 9) a) BJ turnover = grams lost as proteinuria + grams catabolized. b) Grams lost as proteinuria/grams catabolized = P: C ratio. c) Grams catabolized = grams lost as proteinuria/P: C ratio. d) Substituting c in a, BJ turnover = grams lost as proteinuria + (grams lost as proteinuria/P: C ratio). This second method requires only that the P: C ratio and the grams of Bence Jones excreted per day be determined. (Figure 2 , ZO; Table II , ZO no. 2), there was a rapid decline in the serum protein-bound radioactivity and a rapid rise of the free iodide in the plasma to 2% of the injected dose, indicating a buildup of iodide in the body water to 16% of the injected dose following protein catabolism. After reaching a peak, the free iodide in the body water fell slowly, indicating moderate impairment of renal excretion of iodide. This was confirmed by iv administration of NaI131, which indicated that the ti of iodide excretion was 55 hours, compared to the normal 8 to 12 hours (20) .
There was a gradual decrease in the whole body radioactivity as radioactivity was excreted in the urine, both protein-bound and as iodide. At the end of 6 days, 28.7% of the administered radioactivity was lost in the urine as I131-labeled Bence Jones protein, and 31.7% was excreted as free iodide. The fraction of the plasma protein radioactivity lost in the urine per hour, the "proteinuric rate," was 2.5% per hour in ZO (Table II) . The fraction of her plasma protein-bound radioactivity converted to iodide per hour by catabolism of the iodinated protein, termed "catabolic rate," was 2.9%. The higher catabolic rate indicates that catabolism played a slightly greater role than excretion in the loss of Bence Jones protein in this patient.
The relative contributions of excretion and catabolism to protein loss can be expressed as the proteinuric: catabolic (P: C) ratio. In patient ZO, the preceding data indicate a P: C ratio of 0.86. This ratio can be checked from the cumulative excretion of iodide and protein-bound radioactivity in the urine throughout the study (Equation 8b). In ZO the P: C ratio calculated in this way is 0.91, in sufficiently good agreement with the figure of 0.86 obtained above to confirm that catabolism contributed more than excretion to protein loss and that the estimate of the iodide pool used for the determination of the catabolic rate was reasonable.
At the time of study, ZO had a serum Bence Jones protein concentration of 1.3 g per 100 ml and a plasma volume of 2,665 ml. Thus the total circulating Bence Jones protein was accounted for. In 6 of the 7 studies that were carried to the point that less than 2% of the administered radioactivity remained in the plasma at the completion of the experiment, from 6 to 34%o of the dose could not be accounted for. This will be discussed further later in this report.
The other Bence Jones turnover studies performed on Patient ZO, using another preparation of her urinary Bence Jones protein, her serum Bence Jones protein (Figure 4) , and a urinary Bence Jones protein from patient SE (Figure 3 ), gave data of the same order as that discussed above (Table II) . The mean proteinuric rates in the individual studies ranged from 1.4 During the first day, when the majority of the administered protein was catabolized, radioiodide accumulated rapidly in the serum and body water ( Figure 3 ) and was quickly cleared in subsequent days consistent with normal renal function. These two patients synthesized 2. Patient FL had chronic nephritis with extreme renal functional impairment (BUN, 174 mg per 100 ml serum). Although this patient catabolized the labeled protein at a rate of 2.8% of the plasma pool per hour, less than 1 % of the dose was excreted as iodide in the first 24 hours, and only 18%o was excreted in 6 days because of impaired renal function. Discussion Methodological. The metabolism of slowly catabolized serum proteins has been successfully studied with proteins labeled in vivo with C14 or N15 amino acids or in vitro with I131. Certain assumptions inherent in some techniques of analyzing protein turnover data are not fulfilled when proteins with a very short survival are studied, and new methods of conducting the studies and analyzing the data must be used. Studies using labeled precursor amino acids give spuriously long protein survival values because of persistence of labeled precursor. This represents a relatively minor error in the study of albumin and y-globulin, which have survival tj of more than 20 days, but makes accurate studies of proteins with survivals of a few hours impossible. Because the I131 label is not reutilized in patients receiving iodide solutions, this isotope was used in our studies of Bence Jones protein metabolism.
In the majority of metabolic studies using I131_ labeled proteins, results have been expressed either in terms of the tj of protein survival, derived from a semilogarithmic plot of the plasma or whole body radioactivity curves (21, 22) , or as daily urinary activity expressed as a percentage of the retained body radioactivity. These methods of analyzing the data normally require the following assumptions. a) The labeled protein behaves in the body in the same way as unlabeled protein. b) Catabolism and loss of protein occur from both the intravascular and extravascular compartments in proportion to the mass of proteins in these pools. c) The proteins in the various pools are in rapid exchange, and after an initial distribution phase, the specific activity of labeled proteins is the same in all pools. d) The rate of excretion of iodide liberated by a breakdown of the labeled protein should be very rapid compared to the rate of protein catabolism. Campbell, Cuthbertson, Matthews, and McFarlane (23), McFarlane (24), Lewallen, Berman, and Rall (25) , and Veall and Vetter (26) , however, have presented evidence that catabolism of the serum protein occurs in the vascular compartment or a pool that equilibrates very rapidly with the intravascular pool. Proteinuria also clearly represents loss from the intravascular pool. Gitlin and associates (19) have shown in patients with significant proteinuria that specific activities of proteins are seldom uniform in all compartments and that at sites in close temporal proximity with the intravascular pool, where protein loss and catabolism occurs, there may be a much lower specific activity than in the extravascular pools. Thus assumptions b) and c) are not fulfilled, but when the rate of catabolism is low relative to rates of distribution between compartments, the error in calculation of the rate of protein catabolism from whole body radioactivity curves is small. When, as with Bence Jones proteins, rates of catabolism and loss are very rapid, meaningful data cannot be obtained from whole body radioactivity curves alone or from urinary data expressed in terms of whole body radioactivities. For this reason, in our study, both the daily excretion of protein-bound radioactivity (proteinuric rate) and the release of iodine from the catabolized Bence Jones protein (catabolic rate) are expressed in terms of the mean plasma protein-bound radioactivity for that collection period. This assumes that catabolism occurs in a pool closely associated with the plasma but does not require that the size of the extravascular pool be known or that the various pools be in equilibrium.
Another assumption in the use of whole body radioactivity curves or curves of urinary radioactivity alone is that labeled iodide be promptly excreted after catabolism of the protein. This requirement was not met in the present studies.
In ZO and DR, in whom 2.91% of the intravascular Bence Jones protein was catabolized per hour, only 1.1% of the 1131 body iodide was excreted per hour (tj = 55 to 66 hours as determined with NaI131 given intravenously before the protein turnover study). In the extreme case of patient FL, with marked renal functional impairment, there was significant catabolism of Bence Jones protein but hardly any detectable excretion of radioiodide for the first few days of the study, the majority of the radioiodide released from protein catabolism being retained in the body water. Since a similar buildup of radioiodide in the body water occurs to some extent in all patients, one must consider not only radioiodide excreted in the urine but also the alteration in radioiodide in the body water in calculating the rate of catabolism of Bence Jones protein. The significance of relative delay in iodide excretion is not limited to the study of Bence Jones proteins but applies equally to all protein turnover studies where the rate of catabolism is high, as it is in exudative enteropathy, fibrinogen turnover (27) , and such, or where the fractional excretion rate of iodide is low, as it may be in renal disease.
The problem posed by delayed iodide excretion may be handled, using different radioisotopes of iodine, by studying the metabolism of iodide simultaneously with that of the iodinated proteins. Although this was not done in this study, the proportion of radioiodide in the plasma was determined throughout, and by assuming a factor of eight for the ratio of total body to plasma iodide, the radioiodide in the body water could be estimated. Several observations indicate that a factor of eight was appropriate to the present work.
Factors greater than eight are precluded since they would result in values for total body radioactivity greater than the administered dose. If lower factors are used, a sudden, and highly improbable apparent increase in the extravascular protein-bound radioactivity occurs. The iodide pool size, using the factor of eight, agrees well with previously determined values (20, 28 (Table II) .
Seven studies were carried to the point that only negligible radioactivity was present in the plasma and urine. In one study, all of the injected radioactivity was demonstrated in the urine, but in six of these studies only 66 to 94% of the injected radioactivity was apparently excreted in the urine and feces. The apparent retention of radioactivity could result from incomplete collection of radioactivity lost from the body or from radioactivity retained in metabolically inactive sites. Loss of urine appears unlikely, since the patients were kept on metabolic balance conditions in a nursing unit where complete urine collection is routinely performed. None of the patients excreted significant radioactivity in the stools collected during the study, but loss of activity through the skin was not estimated. Uptake of radioiodide by the thyroid was restricted by the use of Lugol's solution, and no significant localization of iodine in the thyroid was found by surface scanning or, in one patient, by post-mortem for radioactivity in tissue. Although protein-bound radioactivity may be stored inside phagocytic cells, much in the way that thorotrast or other colloidal foreign materials are stored, further study using whole body counting techniques is needed to explain this apparent retention of radioactivity.
Biological. Bence Jones protein was rapidly lost from the plasma into the urine or by catabolism in all patients. The sum of proteinuric and catabolic rates ranged from 2.6%o per hour of the circulating pool of labeled BJ protein to over 42% per hour. This may be compared to a turnover of 0.4% per hour of the circulating pool for 6.6 S y-globulin in five of these patients (29) . Catabo Bence Jones proteinuria, however, the proteinuric rate was high (1. Figure 6 , the Bence Jones protein catabolic rates were relatively low (1.8 to 3.9%) in the nine patients with blood urea nitrogen levels above 30 mg per 100 ml. In five of the six patients with normal blood urea levels, however, Bence Jones catabolic rates ranged from 10 a PSP excretion of 4% in 15 minutes and 22% in 2 hours. These data indicate that the kidney may play a role in Bence Jones catabolism. Although the gastrointestinal tract and the liver have been suggested as major sites of catabolism of albumin and -y-globulin (32, 33) , there is some evidence that the kidney plays a significant role in the catabolism of these proteins (34) , especially when proteinuria and protein reabsorption are prominent.
In two patients (ZO and DR) Bence Jones proteins were readily detected in the serum. An unusually high synthetic rate and low catabolic rate combined to raise the serum Bence Jones protein to levels of 1 to 2 g per 100 ml in each patient. Renal damage's reduction of the Bence Jones catabolic rate indicates one of the means by which Bence Jones proteins may increase to detectable levels in the serum. In a study of ten patients with Bence Jones proteinemia (15) , all were found to have advanced renal disease.
The Bence Jones proteins used in these turnover studies were of the same immunochemical type (Type II). Two types of Bence Jones proteins occur in human disease and differ in their immunochemical and physicochemical properties (35) (36) (37) (38) . Since ZO, DR, and SE Bence Jones proteins used in these turnover studies were of Type II, the information we obtained may not be applicable to Bence Jones proteins of Type I. Also, Bence Jones proteins have been found in two sizes (39, 40) . Some have a molecular weight of about 20,000, equivalent to one L polypeptide chain. Most Bence Jones proteins, however, have a molecular weight of about 40,000 and are composed of two L chains (41) . The labeled Bence Jones proteins used in our study belonged to the latter form, as did the Bence Jones proteins of all recipients with multiple myeloma. Further studies would be needed to determine the metabolic properties of the smaller Bence Jones proteins and of immunochemical Type I Bence Jones proteins.
Patients with multiple myeloma apparently have a much greater rate of Bence Jones protein synthesis than is reflected by the quantity of BJ in the urine. As little as 10% of the Bence Jones protein was excreted by patients forming about 3 g per day. Even in patients having 25 to 30 g excreted Bence Jones protein, less than half of the Bence Jones synthesized per day appeared in the urine. These rates of protein synthesis indicate a vigorous synthetic mechanism. Studies of the turnover rate of relatively small numbers of myeloma proteins in man indicate that 35 g of myeloma protein may be synthesized daily (42) .
The patients with minimal or no Bence Jones proteinuria and normal renal functions, who exhibited a low rate of excretion but a high rate of Bence Jones protein catabolism, may provide some indication of the manner of metabolism of y-microglobulins in normal man. Such components, similar to Bence Jones proteins, have been detected in small amounts in the urine (6) (7) (8) and serum (9) 
